Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares jumped 77% after FDA agreed to review new data on deramiocel for Duchenne muscular dystrophy. The review extension stretches runway; $237.9M cash allows controlled spending through the three-month review—a key survival metric for biotech under approval pressure.